Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881578 | 0.89 | PPARG (0.55) | MAPTPPARGMCL1 | |
| SCHEMBL5881907 | 0.88 | PPARG (0.54) | MAPTPPARGMCL1KDM4EALDH1A1 | |
| SCHEMBL5881789 | 0.88 | PPARG (0.54) | MAPTPPARGMCL1KDM4EALDH1A1 | |
| SCHEMBL6320738 | 0.87 | PPARG (0.46) | MAPTTP53PPARGPTPN5KDM4E | |
| SCHEMBL5882099 | 0.87 | PPARG (0.46) | MAPTTP53PPARGMCL1PTPN5 | |
| SCHEMBL5881695 | 0.86 | PPARG (0.51) | MAPTPPARGMCL1KDM4E | |
| SCHEMBL5882152 | 0.86 | MAPT (0.49) | MAPTTP53POLBPPARGMCL1 | |
| SCHEMBL6134778 | 0.86 | MCL1 (0.41) | MAPTPOLBPPARGMCL1PTPN5 | |
| SCHEMBL5881755 | 0.85 | PTPN1 (0.48) | MAPTTP53PPARGMCL1 | |
| SCHEMBL6322000 | 0.85 | PPARG (0.45) | PPARGMCL1EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | claimed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | claimed |
| WO-2005082414-A2 | CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT | ASTELLAS PHARMA INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | disclosed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | MAPT 3941/4885TP53 4877/4885POLB 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.